Cellular Autoimmune Mechanisms of Narcolepsy Study

Clinical Trial Title

Study on the cellular autoimmune mechanisms of narcolepsy.

Clinical Trial Protocol Description:

The purpose of this study is to determine whether narcolepsy patients with cataplexy exhibit an autoimmune response against the peptide orexin, which is depleted in this condition. A blood sample of 30 mL (about 2 tablespoons) will be taken to measure the participant’s cellular immune response against orexin. Subjects will also be tested for a DQB1 allele that is strongly linked to narcolepsy with cataplexy.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are at least 6 years of age.

You will be excluded from the study if any of the following criteria apply to you:

  • Have narcolepsy without cataplexy.
  • Have a sleep disorder other than narcolepsy.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Igor J. Koralnik, MD

Contact Information

Dom Tucker or Zack Orban

(312) 563-7317 or (312) 563-7304